What is happening in January?

Insight?

 

well, if it is like every other January they will let a bunch of people go, rehire a few spots and absorb the rest....

 

well, if it is like every other January they will let a bunch of people go, rehire a few spots and absorb the rest....

 

It may be more than cosmetic this time around. Pressure is mounting. Management has issued an explicit statement that it will be more 'innovation centric' (assuming such a thing is possible in NVS).
I am guessing divestiture of plants, outsourcing or consolidation of most manufacturing operations, shuttering of process development and a drastic reduction in headcount at the DFW location.

 

Remember May 2014. We had a crappy quarter and they just blindly slashed heads.

 

I heard it was December...would Novartis really lay people off right before the holidays?

 

Novartis would pull Jesus off the cross if it increased profits. Always be ready to leave. 2016 will be the hardest for the dfw people.

 

january will be another eye wash for me investors. The plan they will unveil is nothing different than what we do every quarter.
And that is the problem with JG,openass, riad and all that we spend the whole year planning our work and teams are left with no times to work the plan

 

So any news yet? Are we going through another one before the holidays?

 

We can only hope so!!

 

Surgical will be carved out, given an autonomous while pharma will be under the PH division as opht branch. VC will be sold...

 

it will be business as usual. the leaders sit comfortably at the top while the product portfolio continues to get very old. they'll fire people who have fallen out of their favor. they will spend as little time in front of customers. they will play their little political games and slap buddies on the back. they will continue to get their big stock options and bonuses while the little monkeys with organs run around trying to hit big targets. carry on.

 

Investor patience has run out. To satisfy investors, a total re-alignment of innovation in line with 'innovation' practices at Valeant may be on the horizon - buy innovator drugs and only develop and manufacture. In other words, ax R&D, process dev., outsource HR and analytical. Fort Worth about to become a manufacturing hub only - all R&D to be shuttered.

 

We are now in the process of doing a deep analysis of the Alcon business. We are going business-by-business, looking at the competitive situation; the regulatory; the innovation that’s coming in each of those segments. And we’re developing a growth acceleration plan that we’ll be able to unveil at the January earnings forecast, and we’ll show you how we’re going to get this business back to a descent growth rate.

Jimenez on the Q3 earnings call transcript

 

"Descent" sounds about right.

With nothing new in the pipeline you can expect nothing else.

 

The people who could add to the pipeline and those who had the vision and knowledge to drive the pipeline are long gone.
Alcon now is just another quarter-to-quarter, hire-and-fire, company filled with robots who neither have a stake in its future nor any passion for curing disease.

 

'Beyond number one' arrogance defined.

 

Patanol goes generic Dec..... you can guess what is happening to coverage of the product extensions come January.... not good

 

And isn't pataday going generic in spring?